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Breast Cancer (BC) is the most common cancer and the second most cause of death 
among women. Mutations in BRCA1 and BRCA2 genes confer high susceptibility to 
both breast and ovarian cancer. However, data on the prevalence of the BRCA1/2 
mutations among breast and ovarian cancer patients is limited. The genetic component 
of breast cancer in UAE is largely unknown and no study has evaluated the BRCA 
mutations status in breast and ovarian cancer patients in UAE population. This 
retrospective study aimed to establish mutation frequencies of the BRCA genes in 
breast and ovarian cancer patients from Northern Emirates and sought to examine 
potential association of BRCA carriers and Triple- Negative Breast Cancer (TNBC). 
The study population included patients who underwent BRCA genetic testing at Sheikh 
Khalifa Specialty Hospital (SKSH) to determine hereditary breast/ovarian cancer. 
Mutations in BRCA1 and BRCA2 were analyzed by Sanger sequencing or next 
generation sequencing (NGS) along with Multiple Ligation Probe Amplification 
(MLPA).  
Among 262 patients, 224 (85.5%) had no mutation. BRCA mutations were identified 
in 38 patients (14.5%).  BRCA1 and BRCA2 mutations were detected in 6.9% and 7.6% 
of the patients, respectively.  Variant of unknown significance in BRCA1 was found in 
0.4% of patients (one patient). TNBC accounted for 22% of all patients with Breast 
Cancer (BC) who underwent immunohistochemistry (28/127). Importantly, one novel 
BRCA1 mutation: c. (80+1_81-1) _ (441+1_442-1) dup in exons 3,5,6,7 was observed 
in one patient with ovarian cancer who showed positive family history and age ≤ 45. 
Moreover, two novel deletion mutations were identified in the BRCA2 gene. One 
deletion in exon 5 in ovarian cancer patient who showed positive family history and 
age ≤ 45. The second was a deletion in exons 10-13 observed in male patient with 
breast cancer with age ≤ 45. The current study results will help to establish the spectra 
of BRCA mutations and risks associated with breast and ovarian cancer in UAE 
patients. 
 







Title and Abstract (in Arabic) 
 
بین مرضى سرطان الثدي  BRCA2و  BRCA1نسبة انتشار الطفرات الجینیة 
 والمبیض في اإلمارات الشمالیة
 صالملخ
د أسباب الوفاة بین النساء. یعتبر سرطان الثدي أكثر أنواع السرطان شیوعاٌ و ثاني أح
قابلیة عالیة لإلصابة بسرطان الثدي والمبیض.  BRCA2و  BRCA1 تمنح الطفرات في جینات
في مرضى سرطان الثدي و   BRCA1/2و مع ذلك، فإن البیانات المتعلقة بنسبة إنتشار طفرات
ر معروف و لم التكوین الجیني لسرطان الثدي الى حد كبیر غیسرطان المبیض محدودة. یعتبر 
لدى مرضى سرطان الثدي و المبیض   BRCAتقم أي دراسة بتقییم حالة طفرات سرطان الثدي
في دولة االمارات العربیة المتحدة. تھدف ھذه الدراسة إلى تحدید معدل إنتشار الطفرات الوراثیة 
ى لدى مرضى سرطان الثدي والمبیض من االمارات الشمالیة، كما سعت إل  BRCAفي جینات
 ).TNBC( السلبيسرطان الثالثي و    BRCAفحص العالقة المحتملة بین حاملین سرطان الثدي 
في مستشفى الشیخ خلیفة   BRCAشملت الدراسة على المرضى الذین خضغوا لالختبار الجیني
لتحدید االصابة بسرطان الثدي / المبیض الوراثي. تم تحلیل الطفرات  )SKSH( التخصصي
عن طریق إجراء فحص معرفة التسلسل الجیني  BRCA2و   BRCA1اتالوراثیة في جین
Sanger ) أو تقنیة الجیل الجدید لتحدید التسلسل الجینيNGSضافة إلى فحص التضخیم إل) ب
 ).MLPAمسبار الربط المتعدد (
 BRCAمریض طفرة جینیة في  224مریض، لم یكن لدى  262من إجمالي عدد 
%) . حیث تم العثور على 14.5مریضاٌ ( 38لدى    BRCAات بینما تم تحدید طفر ، %)85.5(
% من المرضى على التوالي. كما تم العثور 7.6 % و6.9بنسبة  BRCA2و  BRCA1طفرات 
% من المرضى (مریض واحد). یمثل 0.4 بنسبة BRCA1على طفرات مجھولة االھمیة في 
الذین یعانون  )28/127(ى % من إجمالي عدد المرض22نسبة  )TNBC( سرطان الثالثي السلبي
من سرطان الثدي و الذین خضغوا لفحوصات الكیمیاء النسیجیة المناعیة 
)Immunohistochemistry.( 
 _ (BRCA1 )c. (80+1_81-1الجدیر بالذكر ھو العثور على طفرة جدیدة في جین 






سنة ولدیھا تاریخ عائلي. عالوة على ذلك،  45، لم تتجاوزعمر ریضة مصابة بسرطان المبیضلم
في حالة  exon   5، احدھما حذف اكسون BRCA2في جین للحذفتم اكتشاف طفرتین جدیدتین 
سنة مصابة بسرطان المبیض و لدیھا تاریخ عائلي. و الحالة الثانیة ھو  45لمریضة لم تتجاوز ال 
، لم یتجاوز ت في مریض ذكر مصاب بسرطان الثديلوحظ exons  10-13سوناتحذف في اك
و المخاطر   BRCAھذه النتائج ستساعد في تأسیس محتوى واضح للطفرات الجینیة سنة.  45ال
 المرتبطة بسرطان الثدي والمبیض لدى مرضى شمال دولة االمارات العربیة المتحدة.
 
اثي، سرطان الثدي والمبیض الور ات العربیة المتحدة،دولة االمار :مفاھیم البحث الرئیسیة
فحص تسلسل الجیني التالي، فحص التسلسل الجیني، فحص ال سرطان الثدي ثالثي السلبیة،
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Chapter 1: Introduction 
 
1.1 Cancer 
Cancer is uncontrolled cell division that can occur in any place of the body. In 
normal cell division, an accurate genome duplication will occur to ensure that the two 
daughter cells will have the same genetic material as their parent cell. Any failure to 
achieve this purpose will develop a genomic instability, which generates random 
mutations including chromosomal rearrangements and different forms of genome 
alterations. The accumulation of these genetic alterations may varies between different 
subgroups of cells and leads to form the heterogeneity of cancer [1-2].   
Cancer cells are distinct from their normal counterparts through six essential 
biological features. In 2002, these biological features were first introduced and defined 
as a cancer hallmarks which includes sustaining proliferative signaling, evading 
growth suppressors (antigrowth), resisting cell death (apoptosis), enabling replicative 
immortality, inducing angiogenesis and activating invasion and metastasis (Figure 1). 
Four additional hallmarks of cancer were introduced in 2011, including deregulating 
cellular energetics, avoiding immune destruction, genomic instability and mutation 
and tumor promoting inflammation [3].  
The pathogenesis of cancer is multifactorial, as for many other malignancies, involving 
interactions between different life style and genetic characteristics. Cancer remains 
one of the most health burden disease worldwide. The incidence of cancer has been 
rapidly increased resulting in over 8.7 million deaths [4]. Based on 2018 GLOBOCAN 
statistics, the total number of cancer new cases was around 18 million while the death 





Figure 1: Global cancer statistics 2018 (GLOBOCAN) [5]. 
In the United Arab Emirates (UAE), the burden of cancer in 2010 was high and 
ranked the third leading cause of non-communicable diseases (NCD)-related mortality 
after cardiovascular and injury [6]. The GLOBOCAN data from 2018 shows that the 
cancer incidence rate reached 135.5 per 100,000 people and the mortality rate was 54.7 
per 100,000 people in UAE [5].  
1.1.1 Breast Cancer 
Breast cancer is the most prevalent type of cancer among women worldwide 
with 25.4% of total cancer cases in 2018 [7]. It considered as serious threat to the 
global development with estimated 1,384,155 new cases and approximately 459,000 
deaths cases. It has been estimated that one every eight women will develop breast 
cancer during her life [8].  
Breast cancer is not a single disease but a complex multifactorial disease 





hormonal, and genetic factors. There are three most common diagnostics markers in 
clinical management of BC patients which are human epidermal growth factor 2 
(HER-2), estrogen (ER), and progesterone (PR). BC cell expression of these receptors 
has an impact in disease progression and also in the therapeutic management. The 
majority of BCs are sporadic, which means it develops from damage to a person's 
genes that occurs by chance after they are born. There is no risk of the person passing 
this gene on to their children. However, the familial susceptibility to BC accounts for 
more than 25% of all BCs [9]. 
BC is the most dominant cancer among women in Arab countries [10]. Women 
in Arab world are diagnosed with breast cancer at more advanced stages, and the 
incidence rate has increased over the past three decades [11]. According to American 
Cancer Society, prediction of new cases of breast cancer in women will reach to about 
3.2 million in 2050 [12]. These statistics demonstrate the vastness of breast cancer 
incidence and its effect on societies worldwide.  
The Health Authority of Abu Dhabi (HAAD) reported that the prevalence of 
breast cancer among all cancers diagnosed in Abu Dhabi reached 20.3% in 2014, with 
an associated mortality rate of 12.2%, making breast cancer the most incident in that 
Emirate [13]. Of all cancer cases, breast cancer in women from the GCC countries is 
the most common cancer type. It was reported by the Gulf Center for Cancer 
Registration that annually, for every 100,000 female there are 53.4 cases of breast 
cancer in Bahrain, 22.8 cases in the United Arab Emirates, 17.5 cases in Saudi Arabia, 
48.2 cases in Qatar, and 46.6 cases in Kuwait [14]. However, the effect of geographical 
and ethnical differences in breast cancer incidence signs the impact of environmental 






Figure 2: Breast cancer prevalence around the world [5]. 
1.1.2 Ovarian Cancer 
Worldwide, ovarian cancer (OC) is the seventh most common cancer and the 
eighth leading cause of cancer-related mortality in females, contributing nearly 4% of 
the total number of new cases diagnosed in 2018 [7]. A number of clinical features are 
considered to affect progression-free-survival and overall survival rates in ovarian 
cancer, which includes disease grade, stage and surgical outcome. There are five main 
histologically defined subtypes of OC which are high grade serous, endometrioid, clear 
cell, low grade serous and mucinous OC serous and mucinous OC. As the majority of 
OC is high grade serous, the studies focused on this subgroup more than others [16]. 
Ovarian cancer, like other types of cancer, may occur spontaneously, and mostly 
developed due to genetic predisposition involving dysfunctional of dominant genes 
[17]. However, more than 23% of all ovarian cancer cases are thought to be hereditary 
[18]. Also, it was reported that in ovarian cancer relatives, the risk of breast cancer is 
All rights reserved. The designations employed and the presentation of the material in this publication do 
not imply the expression of any opinion whatsoever on the part of the World Health Organization / 
international Agency for Research on Cancer concerning the legal status of any country, territory, city or 
area or its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines 
on maps represent approximate borderlines for which there may not yet be full agreement. 













increased and vice versa [19]. In Saudi Arabia, the OC accounted for 2.9% of all 
cancers, whereas in western population it accounted for 3.4%. The median age of OC 
Saudi population (55 years) and Middle East Epithelial OC population (50 years) were 
lower than western population (65 years), which could influence the genetic 
predisposition factors in their ethnicity. Therefore, determination such genetic 
predisposition will make efficient early diagnosis and cancer prevention process [20]. 
1.2 Genetic Mutation and Hereditary Breast and/or Ovarian Cancer (HBOC) 
In human, genes are located on 23 pairs of chromosomes. During the process 
of cancer development, malignant transformation is known to involve genetic and 
epigenetic changes that lead to uncontrolled cellular proliferation and/or abnormal 
programmed cell death (apoptosis). These cellular abnormalities resulted through 
accumulation of mutations that are frequently associated with molecular abnormalities 
in certain types of genes, such as proto-oncogenes and tumor-suppressor genes [8, 10]. 
These mutations can result from genetic predisposition and/or exposure to several risk 
factors such as physical inactivity and sedentary lifestyles, the overconsumption of 
high-caloric and poorly-nutritive meals, an increase in obesity rates, an increase in 
smoking prevalence, elevated air pollutant levels, different forms of ionizing 
radiations, and synthetic chemicals. Mutations are either inherited from a parent 
(germline) or acquired affecting only the cells that grow from the mutated cell 
(somatic). Somatic mutation may determine the phenotype of a particular cancer and 
maybe of clinical value in determining cancer prognosis. However, only germline 
mutations can predetermine an individual’s risk of developing cancer. Among all 






Hereditary Breast and/or Ovarian Cancer (HBOC) syndrome is an inherited 
genetic disorder with high level of risk compared to the normal breast and ovarian 
cancer in related family members [17]. Approximately 5-10% of breast cancer cases 
[18] and about 18% of ovarian cancer cases [22] are due to genetic mutation which is 
thought to be hereditary.  
1.2.1 BRCA1/2 Genes 
Minority of breast cancers can show dominant gene mutations. The most 
common gene mutations are those affecting the Breast CAncer 1 (BRCA1) and BReast 
CAncer 2 (BRCA2) genes [8]. BRCA genes, important tumor suppressor genes, are 
involved in DNA damage repair and recombination, cell-cycle checkpoint control, 
apoptosis and transcriptional regulation [23]. BRCA 1 and 2 genes were reported and 
identified as breast cancer susceptibility genes for the first time in 1994 and 1995 
respectively. Since the time of their discovery, the number of studies reporting the 
frequency of mutations in these genes in high-risk breast and breast-ovarian cancer 
families have been increased largely. The breast cancer susceptibility gene BRCA1 is 
expressed in several tissues including breast and ovary. BRCA1 gene (Figure 3) is a 
large gene extend to about 100 kb of genomic DNA. It consists of 24 exons, the first 
and fourth exons are non-coding [24]. Eleventh exon is the largest exon providing 
more than 60% of the whole coding sequence of BRCA1 gene [25]. The final product 
of the protein composed of 1863 amino acids, produce about 220 kd nuclear protein. 
This BRCA1 gene product contains a protein motif, a Ring Finger domain near the 
amino acid terminus and a conserved acidic carboxyl terminus that functions in 
transcriptional co-activation. It was proven that BRCA1 protein plays a crucial part in 





important in the stability of the genome and essential for the repair of damaged DNA.  
BRCA1 protein reacts with RAD51 protein during homologous recombination and 
double strand break repair [23]. The BRCA2 gene (Figure 3) is larger compared to 
BRCA1, composed of 27 exons, where one is non-coding. It codes for a protein of 3418 
amino acids that produce a nuclear protein of 380 kd. BRCA2 gene has a different 
structure than BRCA1 and the protein lacks a well-defined functional domain. Also, 
the BRCA2 protein reacts with RAD51 protein and during this cross interaction with 
RAD51, both BRCA1 and BRCA2 interrelate at sites of DNA synthesis after the 
induction of DNA damage. Thus, the proteins made by BRCA1 and BRCA2 genes are 
both essential for repairing damaged DNA and any changes in these genes may lead 
to hereditary predisposition to breast and ovarian cancer [24].  
1.2.2 BRCA1/2 Genes Mutations 
Mutations in BRCA genes induce defective DNA repair mechanisms, which 
are associated with the risk of developing breast and/or ovarian cancers. Changes in 
BRCA genes are spread all over the entire gene. Different mutations have been reported 





that exceeds 600 and 400 in BRCA1 and BRCA2, respectively. Most types of gene 
mutations considered to be risky and disease-causing that produce a defective and non-
functional protein. There are several forms of mutations reported in BRCA genes such 
as frame shift mutation when either deletion or insertion (indels) of one or more 
nucleotides resulting in missing or non-functional product, nonsense mutation when 
change in one nucleotides produce a stop codon that terminate the protein, or splice 
site alternations that affect the DNA identity and results in abnormal protein [24]. 
About 12% of women in the general population will develop breast cancer sometime 
during their lives and about 1.4% of women in the general population will develop 
ovarian cancer sometime during their lives. One in 400 to 1,000 persons in the overall 
population are expected to have a germline mutation in BRCA1 and BRCA2 genes that 
passed down through their families known as autosomal dominant predisposing genes 
[27]. Some studies showed that a mutation that found towards the 5’-end of BRCA1 
gene tends to develop ovarian cancer whereas mutation towards the 3’-end seems to 
develop breast cancer which means that there is a possible relation between the 
mutation site and the corresponding phenotype [25]. Inherited deleterious mutations 
in the BRCA1 or the BRCA2 genes are associated with an increased risk of developing 
breast and/or ovarian cancer in both woman and men. Women with an inherited 
BRCA1 mutation have a lifetime risk of 65-80% of developing breast cancer and 37-
62% of developing ovarian cancer, while BRCA2 carriers have a lifetime risk of 45-
85% for breast cancer and 11-23% for ovarian cancer. There is an increased risk of 
developing several other cancers in addition to breast and ovarian cancer among BRCA 
carriers. BRCA1 mutations may increase a woman’s risk of developing fallopian tube 
cancer and peritoneal cancer. Men with pathogenic BRCA1 or BRCA2 mutations have 





mutations (6%). Men and woman with BRCA1 and BRCA2 mutations maybe at 
increased risk of pancreatic cancer, stomach, and head and neck. Together, BRCA1 
and BRCA2 mutations cause about 20-25% of hereditary breast cancers. In addition, 
mutations in BRCA1 and BRCA2 account for around 15% of ovarian cancers overall. 
Studies on BRCA1 mutation occurrence suggested that nearly half of the families at 
high risk for breast cancer carried BRCA1 mutation. However, other analysis suggests 
that the actual incidence of BRCA1 in high risk families (>3 cases of breast and/or 
ovarian cancer) might be as low as 12.8% to 16%. It has been observed that large 
variation in the prevalence of BRCA1 mutations in high risk families of different 
countries more common than the prevalence of BRCA2 mutations [19, 25, 28, 29]. 
1.3 Triple Negative Breast Cancer (TNBC) 
Triple-negative breast cancer is an aggressive subtype of breast cancer with a 
higher risk of both local and distant recurrence and poor overall prognosis and it 
accounts for about 10-20% of all cases of breast cancer. TNBC is characterized by a 
lack of the expression of estrogen (ER), progesterone (PR) and human epidermal 
growth factor 2 receptors (HER2/neu), thus, no validated molecular targets for 
treatment are available .TNBC shows an estimated range between 10% and 20% of all 
breast cancers and having a family history of TNBC and/or BRCA mutations may 
increase the possibility of having TNBC [30].  It has been unclear how much BRCA1/2 
mutation frequency may influence the expression of ER, PR, and HER2/neu [31]. With 
the development of targeted therapies for breast cancer patients, designation of 
treatment regimens has become more specific, and breast cancer patients with BRCA 
mutations should be treated differently from the patients without BRCA mutations. The 





1.4 Prevalence of BRCA1/2 Gene Mutations 
The overall prevalence of pathogenic BRCA1/2 gene mutations is low in the 
general population (~0.2-0.3%). This prevalence is increased to approximately 3% in 
women with breast cancer, 6% in women with breast cancer onset at young age (before 
the age of 40), and higher prevalence is associated with a positive family history of 
breast or ovarian cancer (20%) [32]. Although it has been demonstrated that the overall 
prevalence of BRCA1 or BRCA2 oncogenic mutations may differ widely according to 
the study populations, other studies conclude that mutation prevalence is similar across 
diverse races and ethnicities [33-34]. 
1.4.1 Prevalence of BRCA1/2 Mutation in the World 
Recent studies indicate that there is a significantly variation in the prevalence 
of BRCA1 or BRCA2 mutations among ethnic groups and geographical areas. 
Mutations in BRCA1 and BRCA2 are more common in certain racial/ethnic 
populations. There are common mutations in specific population that have been 
described among Ashkenazi Jews population [35] as well as patients of Spanish 
ancestry and that due to common ancient ancestor [36]. Founder BRCA1 and BRCA2 
mutations have also been found in several European populations in Austria, Slovenia, 
Italy, France, Spain, Portugal, Belgium, the Netherlands (Holland), Germany, Czech 
Republic, Slovakia, Hungary, Greece, Cyprus, Denmark, Sweden, Norway, Finland, 
Iceland, the United Kingdom, Ireland, Poland, Latvia, Lithuania, Estonia, Belarus, and 
Russia [36]. Prevalence of BRCA1 and BRCA2 mutations varied widely between key 
clinical and demographic subgroups and across countries. Data from Table 1 were 
adopted from Armstrong et al. [37], which summarizes the prevalence of both genes 





different stage of breast cancer and different hormone receptor status. The highest 
germline mutation of BRCA was reported in the United States [37].  
Table 1: Prevalence of Germline BRCA Mutation Internationally (Unselected for 
Family History, Age, Sex, or Ethnicity) [37]. 

























Mixed 207 11.1 4.3 15.4 
Couch et 
al. [56] 
NR/unclear 1824 8.5 2.7 11.2 
Tung et al. 
[61] 
HR+/HER2- Stages I-III 301 1.7 3.3 5 
Mixed 
Stages I-III 488 3.7 2.5 6.1 
Bayraktar 
et al. [62] 
Metastatic 
BC 
195 15 6 21 
Vidula et 
al. [63] 



























Metastatic 407 0.7 2 2.7 
South 
Korea 
Kim et al. 
[69] 










13 23.1 30.8 53.8 
Abbreviations: BC, breast cancer; BRCA, BC susceptibility gene; HER2-, human epidermal growth factor 







1.4.2 Prevalence of BRCA1/2 Mutations in the Arab Countries 
The incidence and mortality of cancer in Arab countries is increasing rapidly 
and this will obstruct human development and well-being. The most common cancer 
among women in Arab countries was Breast cancer with 49.9% and Ovarian cancer 
with 5% in 2012. WHO estimated that by 2030, there will be an increase of 1.8 fold in 
cancer incidence in the Gulf States and the Eastern Mediterranean region [38]. The 
number of cancer researches and publications from Arab region is considered low 
compared to worldwide publications and this due to less number of researchers in this 
field, the high cost of research and low research output [10]. This explains the rarity 
of high quality data on BRCA mutations in Arab populations. Breast cancer is the first 
leading cause of all cancer deaths among Arab females with approximately rate of 14 
to 42% of all female cancers in Arab region [18]. According to Abdulrashid et al. [18] 
it has been shown that HBOC patients in Arab countries have BRCA mutations and the 
prevalence of BRCA2 mutations were more common (17%) than BRCA1 mutations 
(11%) among the breast cancer patients in the Arab region [18]. 
1.4.3 Prevalence of BRCA1/2 Mutations in the Gulf Countries 
       There are six member countries of the Arabian Gulf Cooperation Council that are: 
Saudi Arabia, Bahrain, Kuwait, Oman, Qatar and United Arab Emirates. Due to the 
migration from Africa, the first Eurasian populations formed and found to be 
genetically related to the original Arabs. In the GCC, populations are divided to genetic 
subgroups, about 48.1% of GCC populations was expats because of recent migration 
of migrant workers [14]. The fact of being descended from the same ancestors has led 
to an increase in genetic diseases among GCC populations and these factors contribute 





prevalence of BRCA1 gene mutation (82.5% of mutations) in Saudi patients is more 
than BRCA2 gene mutations [27]. In Oman, Kuwait and Bahrain, the knowledge about 
the frequency of BRCA1/2 gene mutations among breast cancer patients is not yet 
available. Although it was reported that Qatari breast cancer patients with BRCA1 
mutations carriers were triple negative breast cancer [14]. Although patients with 
hereditary breast and/or ovarian cancer (HBOC) in GCC countries have minimal 
contributions to BRCA1/2 mutations, which is the most reported form of cancer in 
Oman, there is a lack of data about the BRCA1/2 mutation role in breast cancer in the 
region [14].  
The current population structure of the UAE is diverse; a result of a high 
percentage of expatriates (80-90%, residing in the country), compared to a relatively 
small but diverse indigenous population admixed with immigrants from Yemen, 
Oman, North Africa, Iran, Baluchistan, India, and other neighboring regions. 
Approximately 11 million residents in the UAE, however, around 10% only are 
Emirati citizens where endogamous marriage is common, making this segment of UAE 
population relatively homogenous [39-40].  
The knowledge about the prevalence and types of BRCA1 and BRCA2 
mutations involved in breast and ovarian cancer patients in UAE is unavailable. Given 
these considerations, this study aims to determine the prevalence of BRCA1 and 
BRCA2 mutations in patients with breast and/or ovarian cancer; leading to better care 





This study was conducted on patients from northern region of UAE including 
five emirates: Sharjah, Ajman, Ras Al Khaimah, Umm Al Qaiwain, and Fujairah. 
About one third of the population live in the Northern Emirates (Figure 4) [42]. 
 
Figure 4: United Arab Emirates map (Up) showing the northern regions of the emirates 
and UAE population percent by emirate (Down) [41]. 
*Projected Population of each emirate in 2018 based on last known official Population Estimate and 






BRCA1 and 2 mutations contribute to the incidence of breast and ovarian 
cancer among northern Emirates patients. 
1.6 Objectives of the Study 
The main aims of this study are to: 
1- Estimate the frequency of BRCA1/2 genes mutations among cases of 
breast and ovarian cancer in northern Emirates. 
2- Determine the types of BRCA1/2 genes mutations associated with 
breast and ovarian cancer patients diagnosed at the Oncology 
Department, Sheikh Khalifa Specialty Hospital, Ras Al Khaimah, 
UAE. 
3- Investigate the potential relationship between BRCA status and TNBC. 





Chapter 2: Materials and Methods 
 
2.1 Study Design 
This retrospective study was conducted on 262 patients who underwent BRCA 
genetic testing to determine hereditary breast/ovarian cancer. 262 unselected breast 
and ovarian cancer patients, diagnosed at any age from July 2015 to August 2020, from 
the Oncology Department, Sheikh Khalifa Specialty Hospital, Ras Al Khaimah, UAE. 
In total, 262 patients were approached in this study during their out-patient visit to the 
Oncology Department in the hospital. Before the test, all patients had been informed 
about the implications of genetic testing, and interviewed in person for their family 
history of cancer. The oncologist filled the genetic test request form with patient 
information, onset of symptoms, familial history of cancer with specific reference to a 
history of breast or ovarian cancer and family tree for at least three generation. Medical 
records for all patients included in this study were reviewed retrospectively. This study 
was approved by The Institutional Review Board (IRB) in Ministry of Health and 
Prevention in Dubai, UAE (MOHAP/DXB-REC/AAA/No.111/2020). 
2.2 Blood Collection and DNA Extraction 
For each BRCA gene analysis test request, a blood sample was obtained from 
each patient for DNA extraction. Approximately 6 mL of whole blood was collected 
in sterile tubes containing EDTA from all subjects enrolled in this study. Genomic 
DNA was extracted manually (following standard protocol) using the QIAamp Blood 
Mini Kit from QIAGEN manufacturer. The purity and concentration of the extracted 





ThermoScientific. The ultimate concentration used was 25-50 ng/µL and the ratio of 
(A260/A280) was not less than 1.8 to assure the good quality of DNA. 
2.3 BRCA Genes Analysis 
2.3.1 Sanger Sequencing 
BRCA1/2 gene analysis is based on the Gold Standard Sanger Sequencing. 
Human Genome build NCBI36 (BRCA1: Acc. nr: NM_007300, BRCA2:Acc. nr: 
NM_000059), M13 tailed PCR primers were designed and optimized for 100% 
coverage of the coding sequence of the BRCA1 and BRCA2 genes, including sections 
of approximately 50 bp up- and downstream of each exon (24 exons for BRCA1 and 
27 exons for BRCA2). All amplicons can be amplified and sequenced using one 
universal set of PCR conditions. 
For sequencing, PCR using EasySeq™ PCR Plates (Figure 5). 96 well-plate 
containing dried down primer pairs in optimized concentrations, covering both BRCA 
genes. Columns 11 and 12 contain all amplicons, in a total of 15 PCR multiplexes, to 
be used as a No Template Control (NTC), to confirm all results are specific.  
All primer sets have been optimized in concentration and design to be 
compatible with key chemistries [42]. 
Cycle Sequencing is performed with universal sequencing primers: Forward 
primers with -21M13 and reverse primers with M13Rev to enable cycle sequencing 
with universal primers (Figure 6).  





















2.3.2 Next Generation Sequencing (NGS) 
The Ion Torrent system (http://www.iontorrent.com) is unique among Next 
Generation Sequencing technologies in that the detection for sequencing is not based 
upon fluorescent dyes but rather measuring the pH change as the result of the release 
of a H +  ion upon nucleotide incorporation using semiconductor technology (Ion 
semiconductor sequencing). By sequentially adding nucleotides, the machine is able 
to detect which nucleotide has been incorporated into the growing strand.  
The Oncomine™ BRCA Research Assay consists of two pools of AmpliSeq™ 
oligonucleotide primers and associated reagents to generate amplicon libraries for 
next-generation sequencing (NGS) on Ion Torrent™ platforms. The assay is designed 
to provide sensitive and comprehensive sample amplification of all coding regions of 
the human BRCA1 and BRCA2 genes and by using the Ion Chef™ System where the 
library preparation is automated.  
2.3.3 Multiple Ligation- dependent Probe Amplification Analysis (MLPA) 
The MLPA protocol (MLPA®DNA protocol) was performed using the 
instructions provided by the company http://www.mrc-holland.com. The MLPA assay 
was performed using a set of probes for BRCA1 (P002-D1 probe mix), for BRCA2 
(P045/CHEK2 probe mix) and the EK5 SALSA MLPA reagents kit purchased from 
MRC-Holland (Amsterdam, The Netherlands). These probes were used to detect the 
deletion or duplication of exons in the human BRCA1/BRCA2 genes in order to 
determine genetic predisposition to hereditary breast and/or ovarian cancer. Briefly, 
10 ng of genomic DNA in a volume of 5 μl was denatured for 5 min at 98°C, cooled 
and hybridized with MLPA probes (1.5 μl/sample) in the presence of SALSA MLPA 





54°C by adding 32 μl of ligation mixture (3 μl SALSA Ligase buffers A and B, 
respectively, 25 μl demineralized water, and 1 μl SALSA Ligase-65/sample) followed 
by heating to 95°C for 5 min. PCR amplification of the ligation product was performed 
according to the standard protocol. Briefly, 10 μl was added to the mixture consisting 
of (7.5 μl demineralized water, 2 μl SALSA PCR primers and 0.5 μl SALSA 
polymerase/sample) while the samples were left at 4°C or on ice. The samples were 
pre-heated to 60°C for 30 s, followed by 35 cycles of 95°C for 30 s, 60°C for 30 s, 
72°C for 1 min, and a final extension for 20 min at 72°C. From each PCR reaction, 0.7 
μl product was mixed with 9 μl of Hidi Formamide (Applied Biosystems Foster City, 
CA, USA) and 0.2 μl of GeneScan™ 500 LIZ™ dye Size Standard (Applied 
Biosystems, Foster City, CA, USA) and all fragments were separated by capillary 
electrophoresis on the ABI 3500XL Genetic Analyzer (Applied Biosystems, Foster 
City, CA, USA). Sequencer, SeqScape and GeneMarker, unique genotype analysis 
software’s designed for mutation detection, were used in the analysis. 
2.4 Immunohistochemistry  
A total of 127 patients with invasive breast carcinoma who underwent 
mastectomy were tested for ER, PR and the HER-2 status. Briefly, tissue samples from 
each patient were fixed in 10% neutral buffered formalin and embedded in paraffin. 
Sections were deparaffinized in xylene, rehydrated in a graded ethanol series, and 
stained using a Benchmark XT (Roche, Basel, Switzerland). Immunohistochemical 
analysis was carried out with the following monoclonal antibodies: anti-estrogen 
receptor (clone SP1, commercially with appropriate dilution, Roche, Basel, 
Switzerland), anti-progesterone receptor (clone 2E2, commercially with appropriate 





appropriate dilution, Roche, Basel, Switzerland). Staining was assessed according to 
the ASCO/CAP guidelines. 
2.5 Statistical Analysis 
The data, either clinical or genetic findings, were statistically evaluated.  
Statistical significance was performed to find the association between BRCA1 gene 
mutation and other parameters using a two-sided significance level of 5% and 1%. The 
statistical analysis was interpreted and analyzed using the SPSS software version 16 





Chapter 3: Results 
 
3.1 Study Selection and Patient Characteristics 
Total of 262 cases were tested for BRCA1/2 mutation analysis. Patient’s 
clinical characteristics are presented in Table 2. The mean age at the time of diagnosis 
was 46.5 years (range 21-90). 71 out of 262 patients (27%) had a positive family 
history for hereditary breast and ovarian cancer.  
Of total 262, 248 (94.7%) patients were females and 14 (5.3%) were males. 
Total of 186 of the 262 patients (71%) diagnosed with breast cancer and 22/262 (8.4%) 
had ovarian cancer. Patients and relatives of cancer patients from Emirates citizen were 
the most common with total number 230 cases (87.8%), 10 cases from gulf countries 













 Table 2: Clinical Characteristics of 262 Patients. 
  
Wild type  Mutation  All 
    All  BRCA1  BRCA2    
    n=224 (85.5%) n=38 (14.5%)   n=18 (6.9%)   n=20 (7.6%) n=262 (100%) 
Mean age at diagnosis (Range)            46.5 (21-90) 
 45 or less 103 46  25 65.8  11 61.1  14 70  128 48.9 
 More than 45 121 54  13 34.2  7 38.9  6 30  134 51.1 
Cancer type (n) %  (n) %  (n) %  (n) %  (n) % 
 Breast Cancer 166 (74.1%) 20 (52.6%) 
 10 (55.6%)  10 (50%)  (186/262) (71 %) 
 Ovarian Cancer 17 (7.6%) 5 (13.2%) 
 3 (16.7%)  2 (10%)  (22/262) (8.4%) 
 Other 30 (13.4%) 3 (7.9 %) 
 0 (0.0%)  3 (15%)  (33/262) (12.6%) 
 Relative of cancer patients 11 (4.9%) 10 (26.3%)  5 (27.8%)  5 (25%)  (21/262) (8%) 
Gender             
  
 Female 214 (95.5%) 34 (89.5%)  17 (94.4%)  17 (85%)  (248/262) (94.7%) 
 Male 10 (4.5%) 4 (10.5%)  1 (5.6%)  3 (15%)  (14/262) (5.3%) 
Family History             
  
 Positive 50 (22.3%) 21 (55.3%)  13 (72.2%)  8 (40%)  (71/262) (27%) 
 Negative 174 (77.7%) 17 (44.7%)  5 (27.8%)  12 (60%)  (191/262) (73%) 
Ethnicity             
  
 Emirates Citizen 196 (87.5%) 34 (89.5%)  17 (94.4%)  17 (85%)  (230/262) (87.8%) 
 Gulf Countries 7 (3.1%) 3 (7.9%)  1 (5.6 %)  2 (10%)  (10/262) (3.8%) 
 Arabs 12 (5.4%) 1 (2.6%)  0 (0.0 %)  1 (5%)  (13/262) (5%) 
 Others 9 (4.0%) 0 (0.0%)  0 (0.0 %)  0 (0%)  (9/262) (3.4%) 
ER, PR, HER2 receptor status            
  
 TNBC 21 (9.4%) 7 (18.4%)  6 (33.3%)  1 (5%)  (28/127) (22%) 
 Non-TNBC 90 (40.2%) 9 (23.7%)  2 (11.1%)  7 (35%)  (99/127) (78%) 
 Unknown# 111 (49.6%) 22 (57.9%)  10 (55.6%)  12 (60%)  (133/262) (50.7%) 
#Unknown means did not underwent Immunohistochemistry test in SKSH and information is not available.  Abbreviations: ER; Estrogen Receptor, PR; Progesterone Receptor, HER2;Human 





3.2  Prevalence of Germinal BRCA Mutation  
Of total 262, 224 patients and relatives of cancer patients had no mutation in 
BRCA genes (85.5%). 38 mutations were identified in BRCA1 and BRCA2 genes 
(14.5%, 38/262). 18 out of 38 mutations were in BRCA1 gene (6.9%) and 20 mutations 
were in BRCA2 gene (7.6%) as shown in Table.2. All other patients had wild type 
BRCA genes with benign or likely benign mutations. All reported mutations revealed 
pathogenic  mutations except three novel mutations of large exon rearrangements with 
one large duplication involving four exons (Exon 3, 5, 6 and 7) with more than 
11,658bp in BRCA1 gene and two deletions of either one or more exons in BRCA2 
gene. Duplication/ deletions mutations were detected by Deletion/Duplication 
Analysis (MLPA) method. 
Six different mutations in BRCA1 were identified in 18 patients diagnosed with 
BC or/and OC. The most common BRCA1 mutation was frameshift in exon 10: 
c.4065_4068delTCAA   p. (Asn1355Lysfs*10) which was detected in 5 females and 
1 male of one family with a breast cancer history. Same mutation was found in other 
6 unrelated patients, 3 with breast cancer and 3 with ovarian cancer. The mean age for 
those patients with this type of mutation was 39.7 years (Figure 7 and Table 3). 
Another BRCA1 frame shift mutation in exon 10 also c.2704delG (p. 
Glu902Asnfs*98) was detected in two members of one family (cousins) with BC 
family history. A frame shift mutation in exon 2 c.68_69delAG (p.Glu23Valfs*17) 
was detected in a woman with TNBC and positive family history. BRCA1 uncertain 
significant mutation c.4186-10G>A was found in intron side of one BC female patient.  
13/18 patients with mutation in BRCA1 gene (~72%) had a family history of 





Out of 38 BRCA positive cases, 20 patients revealed 12 different mutations in 
BRCA2 gene. The most common mutation detected in BRCA2 gene was the frame shift 
type. 6 BRCA2 mutations revealed in exon 11. Out of 20 patients, 8 (40%) had a 
positive family history of breast cancer. The c.771_775delTCAAA (p.Asn257Lysfs) 
mutation accounted for 15% of the cases with BRCA2 gene mutation, and 
c.2808_2811delACAA (p.Ala938Profs*21) was reported also in other 3 patients 
(15%), one with BC and two with OC with average age 49 and positive hormone 
receptors. Also, the c.1593dupA (p.Glu532Argfs*3) mutation found in two members 
of one family (sister and brother) and one patient all diagnosed with BC (15%). In 
addition, two unreported mutations were identified, first a deletion of exon 5 in an 
ovarian cancer female patient with a positive family history and another deletion of 
four exons (Exons 10-13) in male patient with malignant neoplasm of axillary tail of 
















    Cases with BRCA1 Gene Mutation, Frequency of 
Disease Causing (n=18)     
    N. of Patients  
*BRCA1 Gene Mutation RS ID Exon Number 
Type of 
Mutation (n=18) % Characteristics 
 c.4065_4068delTCAA 
(p.Asn1355Lysfs*10) rs80357508 10 Frameshift 12 67 
9 with positive family history, 6 
members of 1 family with BC, 6 
unrelated patients with 3 BC and 
3 OC, 3 TNBC, average age 39.7 
 c.68_69delAG  (p.Glu23Valfs*17) rs80357914 2 Frameshift 1 6 Positive family history and TNBC 
 c.2704delG   (p.Glu902Asnfs*98) rs886040064 10 Frameshift 2 11 2 members of 1 family (cousins) with BC, average age 48 
 c.(80+1_81-1)_ 
(441+1_442-1)dup    
(MLPA) 
3,5,6,7 Frameshift \Duplication 1 6 
Positive Family history, OC 
patient, Age ≤ 45 
 c.4186-10G>A  (VUS) rs80358172 11 IVS 1 6 TNBC, Age >45 
 c.5323G>C  (p.Glu1775Gln) rs80357432 20 Missense 1 6 TNBC, Age >45 
*The description of nucleotide sequence is in accordance with HGVS nomenclature. DNA mutations are numerated according to NCBI reference sequence 
NM_007300.3 for BRCA1 Bold: most common mutation. Highlighted: Not reported (Novel) mutation. VUS-variant of uncertain significance.  MLPA-
Multiplex ligation-dependent probe amplification analysis. IVS-Intron Variant Sequence.  






Table 4: Characteristics of Patients with BRCA2 Gene Mutation
    
Cases with BRCA2 Gene Mutation, Frequency of Disease Causing 
(n=20) 
    No. of Patients      




mutation (n=20) % Characteristics  
 c.4124delA (p.Glu1375fs) rs886040512 11 Frameshift 2 10 Hormone receptors positive, average age 54, BC and OC patients 
 c.3649delA  (p.Arg1217fs*11) rs864622134 11 Frameshift 1 5 OC patient, age >45 
 c.771_775delTCAAA (p.Asn257Lysfs) rs80359671 9 Frameshift 3 15 3 members of 1 family (2 sisters and aunty) age ≤ 45, all affected with BC 
 c.2808_2811delACAA 
(p.Ala938Profs*21)  rs80359351 11 Frameshift 3 15 
Hormone receptors positive,  average age 49, one 
BC and two OC patients 
 c.7007G>A   (p.Arg2336His) rs28897743 13 Missense 2 10 
Hormone receptors positive, average age 54.5, 
Omani BC female and Prostate cancer male 
patient 
 Deletion in Exon 5 (MLPA)   5 Frameshift \ Deletion 1 5 Positive family history, age ≤ 45, OC patient 
 c.1593dupA (p.Glu532Argfs*3) rs397507272 10 Frameshift 3 15 2 members of 1 family (brother and sister) and 1 patient, all with BC 
 **c.4574A>T (p.His1525Leu) (VUS) rs397507336 11 Missense 1 5 Hormone receptors positive BC,  Positive family history, age > 45   
 c.2654A>G (p.Asp885Gly)  rs398122750 11 Missense 1 5  BC patient , age ≤ 45 
 c.4415_4418delAGAA (p.Lys1472fs) rs397507333 11 Frameshift 1 5  BC patient , age ≤ 45 
c.9109C>A( p.Gln3037Lys)      rs397508037 23 Missense 1 5 TNBC, BC patient, age ≤ 45 
Deletion in Exons 10-13 (MLPA)   10-13 Frameshift \ Deletion 1 5 Male patient with BC, age ≤ 45 
*The description of nucleotide sequence variations is in accordance with HGVS nomenclature. DNA mutations are numerated according to NCBI reference sequence NM_000059.3 for 
BRCA2. Bold: most common mutation. Highlighted: Not reported (Novel) mutation. VUS-variant of uncertain significance. MLPA-Multiplex ligation-dependent probe amplification 





3.3 Association of BRCA Status and TNBC 
Out of 262 cases enrolled in this study, 127 cases were tested for TNBC by 




Figure 8: Immunohistochemical Staining. Representative examples of 
immunostaining for the protein markers ER, PR and HER-2. Negative or positive 
staining. All the slides were analyzed in x 4 and x 20 microscope objectives. 
Brown staining with light blue background refers to positive in ER, PR (B), and 
HER2 (A). Light blue background refers to negative (C) for ER, PR, HER-2 as 





Out of total 127 patients, 28 were TNBC (22%). 6 of these TNBC patients 
revealed a BRCA1 gene mutations (21.4%) and one patient had a BRCA2 mutation 
(3.6%). Other 21 patients didn’t show any mutation either in BRCA1 or BRCA2 genes 
(75%). Taken together, BRCA1 mutation carriers were more likely to have TNBC than 
those of BRCA2 carriers (Figure 9). 
 
Figure 9: Association of BRCA status and TNBC. Unknown indicated patients who 











3.4 Correlation of BRCA1 Gene Mutation with Different Factors 
According to Chen et al. [31], BRCA1 carriers were more likely to have TNBC 
than those of BRCA2 carriers or non-BRCA1/2 carriers among patients with breast 
cancer [31]. Also, the correlation of BRCA1 gene mutation with different factors 
including TNBC, age and familial history was studied. The results showed that patients 
with BRCA1 gene mutation is significantly correlated with young age (p < 0.01), and 
family history (p < 0.05) while TNBC (p =0.17) alone was not associated with 
significant risk (Table 5).  
 
 
 BRCA1 Mutation 
  





Patients % n P 
Age, years 262 
0.000** (< 
0.01) 
≤ 45 11 (4.2%) 117 (44.7%)   
>45 7 (2.7%) 127 (48.5%)   




BC or OC 
    262 0.02* (< 0.05) 
No 5 (1.9%) 186 (71.0%)   
Yes 13 (5.0%) 58 (22.1%)   
     
  
TNBC 127  
Yes 6 (4.7%) 22 (17.3%)   
No 2 (1.6%) 97 (76.4%)   
Abbreviations: BC: breast cancer; TNBC: triple-negative breast cancer, n: population size.  
*Two-sided significance level set at 5%. 
**Two-sided significance level set at 1% 





3.5 Novel BRCA1/2 Mutations Among UAE Population in Northern Emirates 
In Tables 3 & 4, 15 mutations were found and these mutations had been 
reported in different databases such as ClinVar, Breast Cancer Information Core 
(BIC), Varsome, AlAmut and/or HGMD2019. Three Novel mutations were detected 
by MLPA of a large exon rearrangements first, a duplication of 4 exons (Exon 3,5,6, 
and 7) in BRCA1 gene of a 43 years old emirate female who have been diagnosed as 
an OC patient with a family history of BC. Other two novel mutations were found in 
BRCA2 gene with a deletion of one exon (Exon 5) of a 39 years old female patient 
with family history of malignant neoplasm of ovary. Also large deletion of 4 exons 
(Exon 10-13) was detected in a 42 years old male patient with malignant neoplasm of 








Figure 10: Novel BRCA1/2 mutations detected by MLPA analysis workflow in GeneMarker software in this study. Part of an MLPA analysis report 
(GeneMarker v3.0.1) of BRCA1 in A and BRCA2 in B and C. The resulting peak ratios are plotted in the ratio plot above, and are reported for each case in 
the Report Table to the right. (Upper: Four Duplications, middle: one deletion, and bottom: Four Deletions). 
Case: a 43 years old emirate female who have been diagnosed as an 




















Chapter 4: Discussion 
 
Cancer poses one of the major health problem challenges worldwide. BRCA1/2 
germline mutations are responsible for genetic predisposition and may increase the 
risk for breast and ovarian cancer [43]. To date, few studies have been reported on 
BRCA associated breast cancer in the Arab world. In the present study, unselected 
breast or/and ovarian cancer patients with one of the following high-risk criteria were 
eligible for the BRCA mutation analysis:  a first- degree relation with a known mutation 
in a cancer susceptibility gene, history of TNBC in family member, male breast cancer, 
first or second degree relative with breast or ovarian cancer at age ≤45 years.  
According to several studies and reports across the globe, prevalence of BRCA 
mutations varies widely among different populations. This variation can be attributed 
to the effects of founder mutations and environmental factors as well [44-45]. In 
Western countries, the genetic testing for breast cancer have become standard clinical 
management for selected patients. However, in Arab countries it is still less managed 
and genetic testing is not well-established yet. Only few studies reported BRCA 
mutations among breast and ovarian cancer in the Eastern and Arab countries. 
According to these studies, the BRCA1/2 mutation pooled estimate was about 20% 
among patients with both breast and ovarian cancer [12]. 
To date as per the documented literature, this is the first study in UAE that used 
genetic analysis methods to evaluate the prevalence of germline BRCA mutations in 
breast and ovarian cancer patients. The analysis was made on patients unselected for 
age, family history, gender or the expression of hormonal receptors status. This 
retrospective study enrolled patients between July 2015 and August 2020 at Sheikh 





the Northern Emirates. The results show that the prevalence of the BRCA1/2 mutation 
among the 262 cases enrolled in this study is 14.5% (38/262).  
The results of this study were consistent and can be further ascertained with a 
recent publication (March 2019) by Abdulrashid et al who report BRCA1/2 prevalence 
among HBOC /HBC based on 14 selected studies from different Arab countries. Eight 
studies from North Africa (3 Morocco, 2 Algeria, 2 Tunisia, 1 Egypt), four from 
Middle East (2 Lebanon, 1 Palestine, 1 Jordan) and two studies from GCC (1 Saudi 
Arabia and 1 Qatar) (Table. 1). In Middle East countries, the pooled prevalence of 
BRCA mutations was high ~ 28%, followed by the GCC countries with pooled 
prevalence ~22%, and the pooled prevalence was 16% in North Africa [18].  
Globally, the prevalence of BRCA1/2 mutations was also estimated in an 
international publication by Armstrong et al. [37], where a 70 large studies reported 
BRCA1 and/or BRCA2 mutation prevalence data in BC patients across the following 
12 countries: (33 USA), (11 South Korea), (4 United Kingdom), (4 Spain), (3 
Germany), (3 Italy), (2 Canada), (2 Australia) , (2 Russia), (2 France), (1 Japan) and 
(3 Israel). The prevalence of germline BRCA mutations enrolled in unselected 
population on any basis other than breast cancer was clearly shown in Table.1, where 
the highest prevalence was reported in United States study with 15.4% and the lowest 
prevalence was reported as 2.7% in a French study [37]. 
The prevalence of BRCA1 and BRCA2 in this study population were 6.9% and 
7.6% respectively.  Data from Arab region studies showed that BRCA2 is the most 
common type mutation among HOBC patients with an estimated pooled prevalence of 
17% [18]. Likewise, among Asian populations BRCA2 mutations are more common.  
Western population showed a different pattern, where BRCA1 mutations were more 





10.7% [27]. BRCA mutations prevalence could vary widely within demographic 
groups and over countries 
In this study, 18 mutations were reported of both BRCA genes in 38 breast 
and/or ovarian cancer patients. In addition to sequencing method, MLPA was also 
performed for all patients’ samples. The results showed a number of rearrangement of 
BRCA gene exons either deletion or duplication of one or more exons in BRCA1/2 
genes. Most of these mutations were frameshift deletions (10%) in BRCA2, 
duplications (5.6%) in BRCA1 gene. Some common BRCA1/2 mutations were found 
and reported previously in the GCC, Arab Countries and world populations. For 
example, the most abundant BRCA1 mutation in this study c.4065_4068delTCAA 
(p.Asn1355Lysfs*10) was found twelve times in eight female patients and one male 
patient with strong family history of breast cancer and also this mutation is prevalent 
in GCC , Middle East, Europe populations [14, 36].  
Another mutation was found in BRCA1 gene, c.66_67AG (p.Glu23Valfs*17) 
which was detected in a migrant woman worker from India with breast cancer. Also, 
this mutation accounted for the 30.4% of the BRCA1 mutations and is common in 
Spanish and Ashkenazi Jewish populations. Ovarian cancer patients are more likely to 
carry this type of mutation [36].  
Three most common pathogenic frameshift mutations found in BRCA2 gene 
are c.1593dupA (p.Glu532Argfs*3), c.771_775delTCAAA (p.Asn257Lysfs) and 
c.2808_2811delACAA (p.Ala938Profs*21). All these mutations were detected in 
emirate families with breast cancer history. First c.1593dupA (p.Glu532Argfs*3), was 
found in one sister and brother, the second c.771_775delTCAAA (p.Asn257Lysfs) in 
two sisters of another family and the third mutation c.2808_2811delACAA 





[31]. A missense mutation c.7007G>A   (p.Arg2336His) was found twice in Omani 
female and male cancer patients and this mutation  has been reported in populations of  
Middle East , Saudi Arabia and Qatar [14][36]. According to a review by Rahman, S., 
and Zayed, H. [14], ClinVar reports confirmed the pathogenicity for BRCA2 c.7007G 
> A and that it can cause disease. Also, this mutation was found in Hong Kong [14]. 
Triple negative breast cancer is aggressive molecular subtype among other 
breast cancer cases because it lacks ER, PR and expression of HER2 receptors. Thus, 
no validated molecular targets are available for the treatment and therefore considered 
a high-risk breast cancer with overall poor prognosis. Of all breast cancers, TNBC 
accounts for about 15%. Reports showed that TNBCs are the predominant cancer 
subtype with a germline BRCA mutation in which the prevalence of the BRCA 
mutation is 10 to 30% [46-48]. BRCA1 mutation shown also to occur more frequently 
at younger age [23]. In this study, BRCA1/2 mutation in TNBC patients was evaluated. 
Among all 127 patients who underwent immunohistochemistry staining in Pathology 
Department of Sheikh Khalifa Specialty Hospital, 28 patients (22%) were identified 
with immunohistologically confirmed invasive, ER, PR, and HER2 negative BC. 
A total of 7 (25%) BRCA mutations were identified in 28 patients who had TNBC. 
In the current screening, the prevalence of the BRCA1 germline mutation was about 
21.4% (6/28), and the prevalence of the BRCA2 germline mutation was about 3.5% 
(1/28). These data revealed that the prevalence of BRCA1 mutations is more common 
than BRCA2 in TNBC patients, and BRCA1 mutation is found more common among 
TNBC patients but not significantly correlated with the BRCA1 mutation.  
These findings are consistent with the data from international studies 
demonstrating that BRCA1 gene mutation were more common (85.7%) than BRCA2 





the predominant molecular profile in patients with a germline BRCA1 mutations [49-
50]. Several studies have evaluated the prevalence of BRCA1 mutations in patients 
with TNBC. Reports showed that the prevalence of BRCA1 mutations in TNBC 
patients varies between populations and from one study to another. Most studies 
included patient populations selected for young age at diagnosis (< 50 years) and 
reported a prevalence ranging from 7.6 to 23% [51-54]. While other studies evaluated 
the frequency of BRCA1 mutations in unselected TNBC patient populations. The 
BRCA1 mutation frequency was 6.5% when unselected women with TNBC were 
evaluated [55]. When selected by age, the frequency of BRCA1 mutations was 2.8% 
in patients diagnosed at age ≥ 50 years [55]. One study showed that BRCA1 mutations 
were detected in 9% of unselected TNBC patients and in 4.8% of women diagnosed at 
age ≥ 50 years [56]. In one large study of unselected TNBC patients (n = 1824), the 
prevalence of BRCA1 mutation was 8.5%. For the 50–59 age group, the prevalence 
was 7.4% [57]. In this study 21.4% (6/28) of TNBC patients, unselected for age and 
family history, were found to carry BRCA1 mutation. These findings are with the 
agreement with previous reports for Asian populations [44-45, 58-59], where BRCA1-
mutated tumors were ER- or PR-negative and had a higher histological grade, but 
exhibited less medullary carcinoma compared to the Western population [25]. Studies 
have shown that TNBC with BRCA1 has a unique morphology and 
immunohistochemical phenotype that explains the susceptibility of breast cancer 
women with germline BRCA1 mutations to be triple negative [30]. TNBC with family 
history may influence the BRCA mutation. Although several studies have evaluated 
the prognostic role of the BRCA1/2 mutation in patients with TNBC, these studies have 
shown inconclusive results. The present study is a small scale screening analysis and 





between TNBC, BRCA carriers, and positive family history was not made involving 
all breast cancer patients enrolled in this study. Thus, a conclusion needs more data 
collection and further investigation.  
Three novel large exons rearrangement of both BRCA1 and BRCA2 genes using 
MLPA were found in two female ovarian cancer patients with strong family history 
and one breast cancer male. One large BRCA1 genomic rearrangements duplication in 
exon 3, 5, 6 and 7 (c.(80+1_81-1)_(441+1_442-1) dup) was detected in a 43 years old 
female patient with ovarian cancer and considered a novel mutation as it was not 
reported in any database yet. As reviewed by Rahman and Zayed [14], the genomic 
rearrangement in BRCA1 that was found in a study of 43 Omani BC female patients 
which only exon 3,5,11,13 and 20 were tested by direct Sequencing and MLPA and 
they identified four large genomic rearrangement were revealed: two duplications and 
two deletions in exons 1 and 2 [14]. 
In BRCA2, one case with a deletion of exon 5 was detected in ovarian cancer 
female patient and there is no available data of the contribution of BRCA2 mutations 
located on exon 5. Another large deletion of four exons in BRCA2 gene was identified 
in breast cancer young male patient and similar to this mutation (deletion of 3 exons 





Chapter 5: Conclusion and Future Recommendations 
 
In conclusion, this study provides a baseline information on the prevalence of 
BRCA mutation in hospital based population in northern emirates. The current findings 
indicate that 14.5% of unselected patients enrolled in this study carried BRCA 
mutations. The present data provide an evident contribution of BRCA1 and BRCA2 
mutation in patients of breast and ovarian cancer. One limitation of this study is the 
low number of patients who underwent TNBC testing. Furthermore, the results suggest 
to collect more data regarding the status of TNBC and BRCA mutations to make a 
conclusive data whether TNBC could be an effective threshold for BRCA genetic test 
and whether to be considered in genetic testing guidelines in UAE in the future. 
Moreover, this study could be extended further by investigating the possible 
association between patients with positive BRCA mutations and the clinical 
histopathology of the cancer.   
To date, there is no large scale study conducted in Arab countries for BRCA 
mutations including UAE. Therefore, it is important to conduct a large scale 
investigation to better understand the contribution and the frequency of BRCA 
mutations in patients with TNBC. This will contribute to genetic counseling for 
mutation carriers, offer better disease management and will definitely play an 
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